References
- 1. Abuhammour W., Habte-Gaber E.: Newer antifungal agents. Indian. J. Pediatr., 71, 253, 2004.
- 2. Andes D.R. et al.: In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother., 52, 3497, 2008.
- 3. Arendrup M.C. et al.: European Committee for Antimicrobial Susceptibility Testing (EUCAST). Methods for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. EUCAST definitive document EDef 7.2 Revision. March 2012.
- 4. Baran E., Dyląg M.: Echinokandyny - wielkocząsteczkowe lipopeptydy o aktywności przeciwgrzybiczej. Przegl. Dermatol., 93, 131, 2006.
- 5. Barry A.L. et al.: Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol., 38, 3457, 2000.
- 6. Bennett J.E., Izumikawa K., Marr K.A.: Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother., 48, 1773, 2004.
- 7. Bormann A.M., Morrison V.A.: Review of the pharmacology and clinical studies of micafungin. Drug Des. Devel. Ther., 29, 295, 2009.
- 8. Carter N.J., Keating G.M.: Micafungin: A review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Paediatr Drugs., 11, 271, 2009.
- 9. Chandrasekar P.H., Sobel J.D.: Micafungin: A new echinocandin. Clin. Infect. Dis., 42, 1171, 2006.
- 10. Chion Ch., Groll A., Walsh T.: New drugs and novel targets for treatment of invasive fungal infections. Oncologist., 2, 120, 2000.
- 11. Choi H.W. et al.: In vitro susceptibilities to caspofungin and micafungin of clinical isolates of Candida species. Korean J. Lab. Med., 26, 275, 2006.
- 12. Dzierżanowska D.: Nowe antybiotyki stosowane w terapii inwazyjnych zakażeń grzybiczych. Zakażenia, 8, 34, 2008.
- 13. Dzierżanowska D. (2007). Patogeny zakażeń szpitalnych. Bielsko- Biała: α-medicapress.
- 14. Dzierżanowska D. (2007). Postacie kliniczne zakażeń szpitalnych. Bielsko-Biała: α-medicapress.
- 15. Eschenauer G., de Pestel D.D., Carver P.L.: Comparison of echinocandin antifungals. Ther. Clin. Risk. Manag., 3, 71, 2007.
- 16. Hashimoto S.: Micafungin: A sulfated echinocandin. J. Antibiot., 62, 27, 2009.
- 17. Ikeda F. et al.: Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med. Mycol., 47, 145, 2009.
- 18. Joseph J.M., Jain R., Danziger L.H.: Micafungin: A new echinocandin antifungal. Pharmacother., 27, 53, 2007.
- 19. Karthaus M., Cornely O.A.: Treatment options in candidaemia. Mycoses, 50, 44, 2007.
- 20. Messer S.A. et al.: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol., 44, 324, 2006.
- 21. Morris M.I., Villmann M.: Echinocandins in the management of invasive fungal infections. Am. J. Health-Syst. Pharm., 63, 1693, 2006.
- 22. Nakai T. et al: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelia forms. Antimicrob. Agents Chemother., 47, 1376, 2003.
- 23. Nguyen K.T. et al.: Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates. Int. J. Antimicrob. Agents., 35, 80, 2010.
- 24. Oliveira E.R. et al.: Antifungal susceptibility testing of micafungin against Candida glabrata isolates. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 105, 457, 2008.
- 25. Pappas P.G. et al.: Micafungin versus caspofungin for treatment of candidaemia and other forms of invasive candidiasis. Clin. Infect. Dis., 45, 883, 2007.
- 26. Pfaller M.A. et al.: Wild-type MIC distributions and epidemiological cut off values for the echinocandins and Candida spp. J. Clin. Microbiol., 48, 52, 2010.
- 27. Pfaller M.A. et al.: In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin and micafungin: Six years of global surveillance. J. Clin. Microbiol., 46, 150, 2008.
- 28. Pfaller M.A. et al.: Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by CLSI - recommended methods. J. Clin. Microbiol., 44, 3533, 2006.
- 29. Pfaller M.A. et al.: Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol., 46, 2620, 2008.
- 30. Pfeiffer C.D. et al.: Breakthrough invasive candidiasis on micafungin. J. Clin. Microbiol., 48, 2373, 2010.
- 31. Prasad R., Kappor K.: Multidrug resistance in yeasts Candida. Int. Rev. Cytol., 242, 215, 2005.
- 32. Quindos G. et al.: In vitro antifungal activity of micafungin. Rev. Iberoam. Micol., 26, 35, 2009.
- 33. Quindos G., Villar-Vidal M., Eraso E.: Activity of micafungin against Candida biofilms. Rev. Iberoam. Micol., 26, 49, 2009.
- 34. Resende M.A. et al.: Prevalence and antifungal susceptibility of yeasts obtained from the oral cavity of elderly individuals. Mycopathologia, 162, 39, 2006.
- 35. Sucher A.J., Chahine E.B., Balcer H.E.: Echinocandins: The newest class of antifungals. Ann. Pharmacother., 43, 1647, 2009.
- 36. Temesgen Z., Barreto J., Vento S.: Micafungin - the newest echinocandin. Drugs Today, 45, 469, 2009.
- 37. Turner M.S., Drew R.H., Perfect J.R.: Emerging echinocandins for treatment of invasive fungal infections. Expert Opin. Emerg. Drugs., 11, 231, 2006.
- 38. White T.C. et al.: Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother., 46, 1704, 2002.